OBJECTIVE: To determine if statin therapy reduces the incidence of severe sepsis and the levels of inflammatory cytokines in patients with acute bacterial infection. DESIGN: Double-blind placebo controlled randomized clinical trial. SETTING: Department of medicine and medical intensive care unit in a tertiary university medical center. PATIENTS AND PARTICIPANTS: A total of 83 patients with suspected or documented bacterial infection were enrolled. We randomly assigned 42 patients to receive 40 mg of simvastatin orally, followed by 20 mg of simvastatin, and 41 to receive matching placebo. MEASUREMENTS AND RESULTS: The study was prematurely terminated due to slow recruitment rate. Here we report the analysis of the secondary outcome: change in cytokines levels at 72 h. Both groups were evenly matched in terms of co-morbidity and severity of illness on admission. Four of the 83 patients enrolled developed severe sepsis, two in each group. No difference was observed in other clinical variables and there were no mortalities. Cytokine levels were randomly assessed in 40 patients (20 in each group). Both TNF-alpha and IL-6 levels were significantly reduced in the simvastatin group (p = 0.02 and p = 0.02, respectively), while no such difference was observed in the placebo group (p = 0.35 and 0.39, respectively). CONCLUSIONS:Statin therapy may be associated with a reduction in the levels of inflammatory cytokines in patients with acute bacterial infections. Large controlled trials will determine if this reduction will translate into a clinical benefit.
RCT Entities:
OBJECTIVE: To determine if statin therapy reduces the incidence of severe sepsis and the levels of inflammatory cytokines in patients with acute bacterial infection. DESIGN: Double-blind placebo controlled randomized clinical trial. SETTING: Department of medicine and medical intensive care unit in a tertiary university medical center. PATIENTS AND PARTICIPANTS: A total of 83 patients with suspected or documented bacterial infection were enrolled. We randomly assigned 42 patients to receive 40 mg of simvastatin orally, followed by 20 mg of simvastatin, and 41 to receive matching placebo. MEASUREMENTS AND RESULTS: The study was prematurely terminated due to slow recruitment rate. Here we report the analysis of the secondary outcome: change in cytokines levels at 72 h. Both groups were evenly matched in terms of co-morbidity and severity of illness on admission. Four of the 83 patients enrolled developed severe sepsis, two in each group. No difference was observed in other clinical variables and there were no mortalities. Cytokine levels were randomly assessed in 40 patients (20 in each group). Both TNF-alpha and IL-6 levels were significantly reduced in the simvastatin group (p = 0.02 and p = 0.02, respectively), while no such difference was observed in the placebo group (p = 0.35 and 0.39, respectively). CONCLUSIONS: Statin therapy may be associated with a reduction in the levels of inflammatory cytokines in patients with acute bacterial infections. Large controlled trials will determine if this reduction will translate into a clinical benefit.
Authors: G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher Journal: N Engl J Med Date: 2001-03-08 Impact factor: 91.245
Authors: Johannes Pleiner; Georg Schaller; Friedrich Mittermayer; Stefan Zorn; Claudia Marsik; Stefan Polterauer; Stylianos Kapiotis; Michael Wolzt Journal: Circulation Date: 2004-11-01 Impact factor: 29.690
Authors: Corinne Alberti; Christian Brun-Buisson; Sylvie Chevret; Massimo Antonelli; Sergey V Goodman; Claudio Martin; Rui Moreno; Ana R Ochagavia; Mark Palazzo; Karl Werdan; Jean Roger Le Gall Journal: Am J Respir Crit Care Med Date: 2004-11-05 Impact factor: 21.405
Authors: Aisling R Caffrey; Tristan T Timbrook; Eunsun Noh; George Sakoulas; Steven M Opal; Victor Nizet; Kerry L LaPlante Journal: Antimicrob Agents Chemother Date: 2017-02-23 Impact factor: 5.191
Authors: Fiona Havers; Anna M Bramley; Lyn Finelli; Carrie Reed; Wesley H Self; Christopher Trabue; Sherene Fakhran; Robert Balk; D Mark Courtney; Timothy D Girard; Evan J Anderson; Carlos G Grijalva; Kathryn M Edwards; Richard G Wunderink; Seema Jain Journal: Clin Infect Dis Date: 2016-05-10 Impact factor: 9.079
Authors: Steffen Christensen; Reimar W Thomsen; Martin B Johansen; Lars Pedersen; Reinhold Jensen; Kim M Larsen; Anders Larsson; Else Tønnesen; Henrik Toft Sørensen Journal: Crit Care Date: 2010-03-09 Impact factor: 9.097
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2010-01-08 Impact factor: 17.440